

## Special Issue

# Studies on Strategies for Enhancing Vaccine Immunogenicity

### Message from the Guest Editor

The immunogenicity of a vaccine is determined by the characteristics of the specific antigens and the specific vaccine formulation used, as well as the characteristics of the immune response and other genetic factors of the target host. Therefore, variables such as antigen concentration and presentation, adjuvant requirements, delivery strategy, vaccine stability and handling, and manufacturing/distribution characteristics can affect population and individual host responses (and therefore, effectiveness). We hope to encourage the introduction of recent developments in this Special Issue, focusing on understanding the molecular mechanisms that trigger protective immune responses from immunization, and evaluating the contribution of adjuvants and immunomodulatory molecules to vaccine immunogenicity and induction of long lasting immunological memory. This Special Issue focuses on the latest research studies that define innovative strategies for enhancing vaccine immunogenicity. Submissions of original articles, systematic reviews, short communications, and other types of articles on related topics are welcomed. All manuscripts will follow standard journal peer-review practices.

### Guest Editor

Prof. Dr. David Scott McVey

School of Veterinary Medicine and Biomedical Sciences, University of Nebraska, P.O. Box 830905, Lincoln, NE 68583-0905, USA

### Deadline for manuscript submissions

closed (31 October 2022)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/99329](https://mdpi.com/si/99329)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).